PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma.
作者信息
Matsumura Noriomi, Mandai Masaki
机构信息
Faculty of Medicine, Kindai University, Osaka, Japan.
Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan.
出版信息
Int J Clin Oncol. 2025 Jul 12. doi: 10.1007/s10147-025-02830-1.
PMID:40646300
Abstract
摘要
Zotero 插件